

New Options for Patients with Hodgkin Lymphoma

Several Novel Clinical Trial Treatment Options for Patients with Newly Diagnosed or Relapsed/Refractory Hodgkin Lymphoma

Eligibility Criteria in General:

- No active hepatitis or HIV
- No impaired cardiac function
- At least 16 years old
- Adequate laboratory values:

Absolute neutrophil count (ANC) \geq 1k/mm³, Platelets \geq 50 k/mm³, Bilirubin \leq 1.5 times the upper limit of normal (ULN), Alanine transaminase (ALT) \leq 2.5 times the (ULN) or aspartate transaminase (AST) \leq 2.5 times the ULN, Serum creatinine \leq 1.5 times the (ULN)

- No CNS lymphoma
- Bi-dimensionally measureable nodal disease
- For relapsed/refractory patients, they must have received standard treatment and have not received treatment within at least 2 weeks prior to starting clinical trial

Procedure:

- Depending on the trial, procedures will differ
- In general, patients are treated and monitored on a weekly basis which in some cases monitoring can be done by referring physicians

Benefits for Patients:

- May help to improve disease remission rates
- May help to improve progression free and overall survival

For Newly Diagnosed Patients:

Protocol # 2007-0144, clinicaltrials.gov ID (NCT00654732)

A Randomized Phase II Study of Rituximab with ABVD versus Standard ABVD for Patients with Advanced-Stage Classical Hodgkin Lymphoma with Advanced-Stage Classical Hodgkin Lymphoma with Poor Risk Features (IPS score $>$ 2)

Protocol # 2009-0801, clinicaltrials.gov ID (NCT01060904)

A Phase I Dose-Escalation Safety Study of Brentuximab Vedotin in Combination with ABVD as Frontline Therapy in Patients with Hodgkin lymphoma

Protocol # SWOG S0816, clinicaltrials.gov ID (NCT00822120)

A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging

For Relapsed/Refractory Patients:

Protocol # 2010-0261, clinicaltrials.gov ID (NCT01258998)

A Phase II Study of MK-2206 in Patients with Relapsed Lymphoma

Protocol # 2008-0805, clinicaltrials.gov ID (NCT00967044)

A Phase I/II of Panobinostat (LBH589) plus Everolimus (RAD001) in Patients with Relapsed and Refractory Lymphoma

Protocol # 2010-0492, clinicaltrials.gov ID (NCT01263899)

A Phase II Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

Protocol # 2008-0769, clinicaltrials.gov ID (NCT00866333)

A Phase II Multi-Center Study of Entinostat (SNDX-275) in Patients with Relapsed or Refractory Hodgkin's Lymphoma

Protocol # 2010-0649, clinicaltrials.gov ID (NCT01217229)

A Phase II Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Hodgkin Lymphoma

Protocol # 2010-0399, clinicaltrials.gov ID (NCT01221571)

A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients with Refractory and/or Relapsed Hodgkin Lymphoma

Protocol # 2010-0065, clinicaltrials.gov ID (NCT01169636)

A Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma

Schedule an appointment or make referral online at <https://my.mdanderson.org> or call (713) 745-5640

For more information about the study, contact PI, Anas Younes, MD, Lymphoma, at 713-792-2860, or ayounes@mdanderson.org or Research Advanced Practice Nurse, Amy Copeland, RN, MSN, at 713-792-9455, or arcopeland@mdanderson.org

For information on related articles or references for this study, visit <http://physicianrelations.org> or <http://clinicaltrials.gov/>

THE UNIVERSITY OF TEXAS

**MDAnderson
Cancer Center**

Making Cancer History®